Insider’s View: Deciphering BioNTech SE ADR (BNTX)’s Financial Health Through Ratios

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The price of BioNTech SE ADR (NASDAQ: BNTX) closed at $120.30 in the last session, down -1.03% from day before closing price of $121.55. In other words, the price has decreased by -$1.03 from its previous closing price. On the day, 0.47 million shares were traded. BNTX stock price reached its highest trading level at $122.465 during the session, while it also had its lowest trading level at $120.12.

Ratios:

We take a closer look at BNTX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.57. For the most recent quarter (mrq), Quick Ratio is recorded 7.40 and its Current Ratio is at 7.54. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on September 24, 2024, Upgraded its rating to Overweight and sets its target price to $145 from $93 previously.

On September 17, 2024, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $96 to $150.

JP Morgan Upgraded its Underweight to Neutral on September 16, 2024, whereas the target price for the stock was revised from $91 to $125.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 08 ’24 when ATHOS KG bought 15,000 shares for $122.01 per share.

ATHOS KG bought 14,756 shares of BNTX for $1,812,078 on Oct 04 ’24. On Oct 03 ’24, another insider, ATHOS KG, who serves as the 10% Owner of the company, bought 50,000 shares for $119.27 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNTX now has a Market Capitalization of 28603250688 and an Enterprise Value of 11562178560. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.84 while its Price-to-Book (P/B) ratio in mrq is 1.40. Its current Enterprise Value per Revenue stands at 4.297 whereas that against EBITDA is -18.604.

Stock Price History:

Over the past 52 weeks, BNTX has reached a high of $131.49, while it has fallen to a 52-week low of $76.53. The 50-Day Moving Average of the stock is 21.86%, while the 200-Day Moving Average is calculated to be 27.66%.

Shares Statistics:

According to the various share statistics, BNTX traded on average about 958.59K shares per day over the past 3-months and 723920 shares per day over the past 10 days. A total of 237.73M shares are outstanding, with a floating share count of 237.11M. Insiders hold about 0.26% of the company’s shares, while institutions hold 17.88% stake in the company. Shares short for BNTX as of 1726185600 were 2682802 with a Short Ratio of 2.80, compared to 1723680000 on 3094342. Therefore, it implies a Short% of Shares Outstanding of 2682802 and a Short% of Float of 5.59.

Most Popular